KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBT (2016 - 2025)

Rigel Pharmaceuticals has reported EBT over the past 16 years, most recently at $22.7 million for Q4 2025.

  • Quarterly results put EBT at $22.7 million for Q4 2025, up 49.22% from a year ago — trailing twelve months through Dec 2025 was $121.8 million (up 563.33% YoY), and the annual figure for FY2025 was $121.8 million, up 563.33%.
  • EBT for Q4 2025 was $22.7 million at Rigel Pharmaceuticals, down from $27.6 million in the prior quarter.
  • Over the last five years, EBT for RIGL hit a ceiling of $60.0 million in Q2 2025 and a floor of -$27.4 million in Q1 2022.
  • Median EBT over the past 5 years was -$3.4 million (2023), compared with a mean of $2.0 million.
  • Biggest five-year swings in EBT: plummeted 166.5% in 2022 and later surged 5923.5% in 2025.
  • Rigel Pharmaceuticals' EBT stood at -$22.7 million in 2021, then soared by 106.17% to $1.4 million in 2022, then tumbled by 47.39% to $737000.0 in 2023, then skyrocketed by 1965.4% to $15.2 million in 2024, then skyrocketed by 49.22% to $22.7 million in 2025.
  • The last three reported values for EBT were $22.7 million (Q4 2025), $27.6 million (Q3 2025), and $60.0 million (Q2 2025) per Business Quant data.